Company profile: Xstrahl
1.1 - Company Overview
Company description
- Provider of superficial orthovoltage X-ray systems for treating skin and bone cancers, dermatological disorders, benign conditions, and for palliative care, with precise non-surgical options. Also offers a compact office-based dual-modality device for non-melanoma skin cancers and keloid scarring, and advanced X-ray platforms for preclinical radiation biology research.
Products and services
- SARRP: Research-grade preclinical irradiation platform enabling clinically relevant radiation experiments with adaptable irradiation capabilities for radiation biology research
- Xstrahl 200: Medical-grade versatile X-ray system that treats superficial lesions, skin cancers, benign conditions, and delivers palliative care using clinically relevant superficial radiation therapy
- Xstrahl 300: Clinical-grade orthovoltage system that delivers targeted X-ray therapy for skin and bone cancers, dermatological disorders, and hyperproliferative conditions with established superficial radiation modalities
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Xstrahl
Oncimmune
HQ: United Kingdom
Website
- Description: Provider of proprietary autoantibody assay technologies for early cancer detection, offering ImmunoINSIGHTS analytical platform to discover and profile autoantibody biomarkers for disease characterization, patient stratification, and response prediction; biomarker discovery services; customizable targeted panels and arrays for immuno-oncology and autoimmune diseases; and bioinformatics and data science with multiomics integration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncimmune company profile →
Paradigm
HQ: United States
Website
- Description: Provider of cutting-edge molecular diagnostics and biomarker-driven clinical trials for cancer patients and industry, using Next-Gen Sequencing and other biomarker analysis to deliver information on the genomic and proteomic landscape of a patient's cancer and potential therapies based on specific characterization of the cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Paradigm company profile →
Allarity
HQ: United States
Website
- Description: Provider of biopharmaceutical oncology therapies and predictive diagnostics for personalized cancer treatment, utilizing DRP Technology to predict patient response and refine patient selection. Pipeline includes Dovitinib for renal cell carcinoma, Stenoparib, LiPlaCis, and 2X-111.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Allarity company profile →
Novigenix
HQ: Switzerland
Website
- Description: Provider of ImmunoTranscriptomic precision medicine solutions for disease detection, therapy optimization, and recurrence monitoring. Swiss company offering the LITOseek AI/RNA platform for immune response profiling, biomarker discovery, drug target discovery, and therapy response prediction; COLOX blood test for early colorectal cancer and pre-cancerous lesions; immunotherapy response prediction; digital cytometry; biomarker testing services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Novigenix company profile →
Shoreline Biosciences
HQ: United States
Website
- Description: Provider of engineered cellular immunotherapies for seriously ill patients, leveraging an iPSC-based modular development system for gene editing to optimize therapeutic profiles. Offerings include iNK cells to target and eliminate cancer cells and iMACs to modify the tumor microenvironment and stimulate an anti-tumor immune response.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Shoreline Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Xstrahl
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Xstrahl
2.2 - Growth funds investing in similar companies to Xstrahl
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Xstrahl
4.2 - Public trading comparable groups for Xstrahl
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →